We are looking for physician perspectives on patients combining GLP-1 receptor agonists with growth hormone–related peptides or recovery stacks. We want practical insights on risks, monitoring, and patient expectations. Questions: 1. Are you seeing patients combine GLP-1 receptor agonists with growth hormone–related peptides, and what concerns do you have regarding muscle loss, metabolic effects, or long-term outcomes? 2. What baseline assessments and follow-up strategies do you recommend for patients on GLP-1 therapies to preserve lean mass and minimize complications? 3. How do you counsel patients who expect rapid or sustained results from combining pharmacologic agents without addressing nutrition and resistance training?